Cells were lysed using RIPA buffer with the addition of proteases and phosphatases inhibitors (Roche, Indianapolis, IN, USA). Quantified lysates were separated on an SDS polyacrylamide gel. The blots were probed with the indicated antibodies as follows:
EGFR, phospho-EGFR (Y1068), YAP1, phospho-YAP (S127), YES and β-TRCP (all from Cell Signaling, Beverly, MA, USA); and actin (Sigma).
Quantitative RT-PCR
RNA was harvested from cells using Trizol. Complementary DNA was prepared using Transcriptor Reverse Transcriptase (Roche). Quantitative PCR was performed using SYBR Green (Applied Biosystems, Foster City, CA, USA). The primers used are listed in Table S2 .
Co-immunoprecipitation assay
Lysis buffer [50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM DTT, 1% containing protease inhibitors and phosphatase inhibitors] was added to the cells. The 
Immunofluorescent staining
The lung cancer cell line cells were plated on a microscope slide and fixed using 4% paraformaldehyde 24 h after plating. Cells were permeabilized by adding 0.1% Triton in PBS for 5 min. Cells were incubated with 1% BSA in PBS containing 1:100 anti-YAP1, YES or EGFR (Cell Signaling) overnight at 4 °C. Mouse or rabbit fluorescent secondary antibody was added (1:500) for 1 h at RT.
Statistical analyses 3
The data were analyzed using Student's t test or one-way ANOVA. P values <0.05 were considered significant. The IHC results comparing the correlation between EGFR mutation and YAP1 expression was performed using Fisher's exact test. 
